Arch Therapeutics to Present at The Biotech Showcase(TM) 2017 Conference on January 10th, 2017
January 05, 2017 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Jan 5, 2017) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5™ devices for use in controlling...
Arch Therapeutics to Present at 9th Annual LD Micro Main Event on December 7, 2016
December 05, 2016 18:03 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Dec 5, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5™ devices for use in controlling bleeding and fluid loss in...
Arch Therapeutics Reports AC5 Topical Hemostatic Device Successfully Stopped Bleeding in Patients on Antiplatelet Therapy in Recently Completed Clinical Study
October 31, 2016 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Oct 31, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of devices for use in controlling bleeding and fluid loss in order to...
Arch Therapeutics Will Present at the 2016 Bio Investor Forum in San Francisco, California October 18-19th, 2016
October 11, 2016 08:10 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Oct 11, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of AC5™ devices for use in controlling bleeding and fluid loss in...
Arch Therapeutics Will Present at the 2016 Aegis Capital Growth Conference in Las Vegas, NV September 20-22, 2016
September 15, 2016 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Sep 15, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5™ devices for use in controlling bleeding and fluid loss in...
Arch Therapeutics Provides Corporate Update at the 18th Annual Rodman & Renshaw Global Investment Conference
September 12, 2016 19:07 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Sep 12, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of AC5™ devices for use in controlling bleeding and fluid loss in...
Arch Therapeutics Will Present 18th Annual Rodman & Renshaw Global Investment Conference in New York City September 11-13th, 2016
August 22, 2016 11:02 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Aug 22, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of AC5™ devices for use in controlling bleeding and fluid loss in...
Arch Therapeutics' President and CEO, Terrence Norchi, MD, Featured on "Small Cap Spotlight" Podcast Broadcasted Globally on Publicwire
August 19, 2016 08:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Aug 19, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a developer of devices for use in controlling bleeding and fluid loss in order...
Arch Therapeutics Reports AC5 Topical Hemostatic Device Meets Primary and Secondary Endpoints in First Clinical Study
August 15, 2016 06:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Aug 15, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of devices for use in controlling bleeding and fluid loss in order to...
Arch Therapeutics Completes Patient Enrollment in Clinical Study of AC5
June 06, 2016 07:57 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Jun 6, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...